Abstracts tagged "SLE and cytokines"

Abstract Number: 1636 • 2014 ACR/ARHP Annual Meeting
Disease Phenotype Is Associated with TH1, TH2 and TH17 Cytokines in Childhood-Onset Systemic Lupus Erythematosus
Karina Oliveira Peliçari¹, Mariana Postal², Renata Brabosa³, Nailu A. Sinicato², Fernando Augusto Peres², Roberto Marini⁴ and Simone Appenzeller⁵, ¹State University of Campinas, Campinas, Brazil, ²Medicine, State University of Campinas, Campinas, Brazil, ³Medicine, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Germany, ⁴Departament of Pediatrics, State University of Campinas, Campinas, Brazil, ⁵Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil
Background/Purpose Childhood-onset Systemic lupus erythematosus (cLES) is an autoimmune disease characterized by periods of activity and remission. There is a wide spectrum of manifestations, such…
Abstract Number: 2517 • 2013 ACR/ARHP Annual Meeting
The Interferon-Alpha Signature In Patients With Serologically Active Clinically Quiescent Systemic Lupus Erythematosus
Amanda J. Steiman¹, Murray B. Urowitz², Dominique Ibanez², Carolina Landolt-Marticorena³, Joan E. Wither⁴ and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴1E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Interferon-α (IFN-α) plays a prominent pro-inflammatory role in SLE. Studies suggest clinical/serologic discordance may illuminate systemic lupus erythematosus (SLE) pathophysiology, as peripheral IFN-α production…
Abstract Number: 1867 • 2013 ACR/ARHP Annual Meeting
Profiling Cytokine Production Of B Cells From SLE Patients Upon TLR9 Stimulation
Julia Sieber¹, Capucine Daridon², Simon Fillatreau³ and Thomas Dörner¹, ¹CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ²Department of Medicine/Rheumatology and Clinical Immunology, Charité University Medicine / German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany, ³German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany
Background/Purpose: Beyond their antibody producing function, B cells have been shown to be potent antigen-presenting and cytokine-producing cells. In systemic lupus erythematosus (SLE), B cells…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].